TRAL (hexocyclium methylsulfate) by AbbVie is tralokinumab-ldrm is a human igg4 monoclonal antibody that specifically binds to human interleukin-13 (il-13) and inhibits its interaction with the il-13 receptor α1 and α2 subunits (il-13rα1 and il-13rα2). Approved for moderate-to-severe atopic dermatitis in adults, older whose disease is not adequately controlled with topical prescription therapies, those therapies are not advisable. First approved in 1957.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
TRAL (hexocyclium methylsulfate) is an oral small-molecule anticholinergic agent approved in 1957 for symptomatic relief of gastrointestinal spasm and related conditions. NOTE: Data conflict detected—product labeled as hexocyclium methylsulfate but MOA describes tralokinumab-ldrm (IL-13 monoclonal antibody for atopic dermatitis); analysis proceeds with regulatory record (hexocyclium, oral tablet, 1957 approval).
Product is in late lifecycle stage with minimal active staffing; limited career growth opportunity on this established brand.
Tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2). IL-13 is a naturally occurring cytokine of the Type 2 immune response. Tralokinumab-ldrm…
Worked on TRAL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Registry of Central Sleep Apnea Patients Undergoing remedē System Implant
Early Feasibility Study of NeoChord Transcatheter Mitral Repair System
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement
Working on TRAL offers very limited career upside; only 1 linked role exists globally, indicating a skeleton team focused on regulatory compliance and medical support rather than growth initiatives. This is suitable only for professionals seeking stable, low-pressure roles in mature brand management or medical affairs support.
1 open roles linked to this drug